Abstract
Prevention through evaluation and treatment of cardiovascular risk factors is an efficient approach to reduce the risk of cardiovascular events, however, the problem remains that the available treatment options are underused. Implementation of cardiovascular disease prevention guidelines into clinical practice is therefore important for decreasing the burden of cardiovascular disease in general population. However, there are many barriers to this process, including questionable relevance of scientific results for clinical practice, personal preferences and expertise of the doctors, patient attitudes, lack of time, and economical factors. All these factors need to be taken into account for any change in the clinical practice to be successful. With respect to cardiovascular disease prevention, insufficient screening for risk factors, inappropriate risk estimation and hesitation to keep to the guidelines-based treatment targets contribute most to inadequate control of risk factors, and this has been repeatedly demonstrated to be difficult to improve. In this context, our studies demonstrate that the emphasis on systematic application of principles of cardiovascular prevention results in improved control of cardiovascular risk factors. Adequate support for transforming guidelines-based knowledge into practicable habit appears therefore important for successful prevention of cardiovascular disease in clinical practice and may translate into substantial reduction of cardiovascular risk in general population.
Keywords: Cardiovascular risk, hypertension, dyslipidemia, cardiovascular risk reduction, guidelines implementation.
Current Pharmaceutical Design
Title:Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Volume: 21 Issue: 9
Author(s): Richard Ceska and Tomas Stulc
Affiliation:
Keywords: Cardiovascular risk, hypertension, dyslipidemia, cardiovascular risk reduction, guidelines implementation.
Abstract: Prevention through evaluation and treatment of cardiovascular risk factors is an efficient approach to reduce the risk of cardiovascular events, however, the problem remains that the available treatment options are underused. Implementation of cardiovascular disease prevention guidelines into clinical practice is therefore important for decreasing the burden of cardiovascular disease in general population. However, there are many barriers to this process, including questionable relevance of scientific results for clinical practice, personal preferences and expertise of the doctors, patient attitudes, lack of time, and economical factors. All these factors need to be taken into account for any change in the clinical practice to be successful. With respect to cardiovascular disease prevention, insufficient screening for risk factors, inappropriate risk estimation and hesitation to keep to the guidelines-based treatment targets contribute most to inadequate control of risk factors, and this has been repeatedly demonstrated to be difficult to improve. In this context, our studies demonstrate that the emphasis on systematic application of principles of cardiovascular prevention results in improved control of cardiovascular risk factors. Adequate support for transforming guidelines-based knowledge into practicable habit appears therefore important for successful prevention of cardiovascular disease in clinical practice and may translate into substantial reduction of cardiovascular risk in general population.
Export Options
About this article
Cite this article as:
Ceska Richard and Stulc Tomas, Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013152521
DOI https://dx.doi.org/10.2174/1381612820666141013152521 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?
Current Vascular Pharmacology Novel Biomarkers/Predictors of Cardiovascular Disease and Cardiovascular Events
Current Vascular Pharmacology Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety The Dopamine D<sub>2</sub> and Adenosine A<sub>2A</sub> Receptors: Past, Present and Future Trends for the Treatment of Parkinson's Disease
Current Medicinal Chemistry Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Impact of Clinical Audit on Adherence to the Guidelines Directed Medical Therapy in Patients Admitted with Heart Failure
Current Drug Safety Alcoholisms Evolutionary and Cultural Origins
Current Drug Abuse Reviews Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases
Current Medicinal Chemistry Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Testosterone Supplementation on Sarcopenia Components in Chronic Patients: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design Thrombin Inhibitors and Anti-Factor Xa Agents in the Treatment of Arterial Occlusion
Current Drug Targets The sdLDL Reduces MRC1 Expression Level and Secretion of Histamin e in Differentiated M2-macrophages from Patients with Coronary Artery Stenosis
Cardiovascular & Hematological Disorders-Drug Targets Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry RAAS Inhibition and Renal Protection
Current Pharmaceutical Design Law-Medicine Interfacing: Patenting of Human Genes and Mutations
Recent Patents on DNA & Gene Sequences Meet Our Editorial Board Member
Current Drug Delivery